0.9380
+0.0005
+(0.05%)
At close: January 24 at 3:00:00 PM EST
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Operating Expense
18,345.0000
18,674.0000
16,303.0000
22,473.0000
17,395.0000
Operating Income
-18,345.0000
-18,674.0000
-16,303.0000
-22,473.0000
-17,395.0000
Net Non Operating Interest Income Expense
1,218.0000
1,198.0000
914.0000
69.0000
314.0000
Other Income Expense
-9,555.0000
-7,990.0000
5,341.0000
-173.0000
-208.0000
Pretax Income
-26,682.0000
-25,466.0000
-10,048.0000
-22,577.0000
-17,289.0000
Net Income Common Stockholders
-26,682.0000
-25,466.0000
-10,048.0000
-22,577.0000
-17,289.0000
Diluted NI Available to Com Stockholders
-26,682.0000
-25,466.0000
-10,048.0000
-22,577.0000
-17,289.0000
Basic EPS
-0.38
-0.37
-0.16
-0.42
-0.35
Diluted EPS
-0.38
-0.37
-0.16
-0.42
-0.35
Basic Average Shares
72,438.2060
69,637.4690
64,736.4930
54,286.6710
49,661.7760
Diluted Average Shares
72,438.2060
69,637.4690
64,736.4930
54,286.6710
49,661.7760
Total Expenses
18,345.0000
18,674.0000
16,303.0000
22,473.0000
17,395.0000
Net Income from Continuing & Discontinued Operation
-26,682.0000
-25,466.0000
-10,048.0000
-22,577.0000
-17,289.0000
Normalized Income
-17,127.0000
-17,476.0000
-15,389.0000
-22,404.0000
-17,081.0000
Interest Income
1,218.0000
1,198.0000
914.0000
69.0000
314.0000
Net Interest Income
1,218.0000
1,198.0000
914.0000
69.0000
314.0000
EBIT
-18,345.0000
-18,674.0000
-16,303.0000
-22,473.0000
-17,395.0000
EBITDA
-18,327.0000
-18,669.0000
-16,298.0000
-22,435.0000
-17,355.0000
Reconciled Depreciation
18.0000
4.0000
4.0000
38.0000
40.0000
Net Income from Continuing Operation Net Minority Interest
-26,682.0000
-25,466.0000
-10,048.0000
-22,577.0000
-17,289.0000
Total Unusual Items Excluding Goodwill
-9,555.0000
-7,990.0000
5,341.0000
-173.0000
-208.0000
Total Unusual Items
-9,555.0000
-7,990.0000
5,341.0000
-173.0000
-208.0000
Normalized EBITDA
-8,772.0000
-10,679.0000
-21,639.0000
-22,262.0000
-17,147.0000
3/31/2021 - 11/13/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NGENF NervGen Pharma Corp.
1.9600
-1.01%
MSCLF Satellos Bioscience Inc.
0.6030
+0.08%
ACXP Acurx Pharmaceuticals, Inc.
0.8716
+5.25%
MSCL.TO Satellos Bioscience Inc.
0.8700
-1.14%
EPRX Eupraxia Pharmaceuticals Inc.
2.9300
-2.01%
NYMXF Nymox Pharmaceutical Corporation
0.0800
-27.27%
4593.T Healios K.K.
271.00
+8.84%
BETRF BetterLife Pharma Inc.
0.1140
0.00%
DAWN Day One Biopharmaceuticals, Inc.
12.21
-2.40%
LRMR Larimar Therapeutics, Inc.
3.5800
-1.38%